<a href="https://laohu8.com/S/ATNF">180 Life Sciences Corp</a>. Stockholders Approve New Incentive Plans and Amendments at 2025 Annual Meeting
180 Life Sciences Corp. has announced the approval of the Fourth Amendment to its 2022 Omnibus Incentive Plan and the new 2025 Option Incentive Plan, following stockholder approval at the recent annual meeting. The Fourth Amendment increases the number of shares available under the incentive plan by 4,000,000, bringing the total to 5,000,000 shares, with provisions for annual increases tied to the company's outstanding common stock. The 2025 Option Plan, initially approved by the board on June 17, 2025, was also sanctioned by stockholders and permits the company to grant stock options, which cannot be exercised prior to stockholder approval. These plans are in line with Nasdaq Capital Market regulations, ensuring compliance and flexibility in equity arrangements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-067354), on July 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.